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Nuclear 3’-end-polyadenylation is essential for the transport, stability and translation of
virtually all eukaryotic mRNAs. Poly(A) tail extension can also occur in the cytoplasm, but the
transcripts involved are incompletely understood, particularly in cancer. Here we identify a
lineage-specific requirement of the cytoplasmic polyadenylation binding protein 4 (CPEB4) in
malignant melanoma. CPEB4 is upregulated early in melanoma progression, as defined by
computational and histological analyses. Melanoma cells are distinct from other tumour cell
types in their dependency on CPEB4, not only to prevent mitotic aberrations, but to progress
through G1/S cell cycle checkpoints. RNA immunoprecipitation, sequencing of bound tran-
scripts and poly(A) length tests link the melanoma-specific functions of CPEB4 to signalling
hubs specifically enriched in this disease. Essential in these CPEB4-controlled networks are
the melanoma drivers MITF and RAB7A, a feature validated in clinical biopsies. These results
provide new mechanistic links between cytoplasmic polyadenylation and lineage specification
in melanoma.
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n the nucleus, nearly all nascent mRNAs become polyadeny-
lated at their 30-end (ref. 1). In the cytoplasm, shortening of
the poly(A) tail usually results in cessation of translation,
decapping and mRNA destabilization2. However, a subset of
mature mRNAs can sustain short poly(A) tails, remaining stable
and translationally silent until reactivated by re-adenylation2,3.
While the identity of the transcripts regulated by cytosolic
polyadenylation and the macromolecular complexes involved are
still not completely defined, main effectors are the four members
of the cytoplasmic polyadenylation element binding family (that
is, CPEB1 to CPEB4). Initially described as essential modulators
of meiosis in Xenopus laevis, CPEBs have been also reported with
key roles in somatic cells, for example in the control of mitosis,
differentiation, cell polarity or motility, among others3–5. These
processes can favour cancer, and therefore CPEBs are raising
great interest in oncology for their potential impact on post-
transcriptional mechanisms of gene reprogramming associated
with tumour development4–7. Nevertheless, the assignment of
specific functions to individual CPEBs has been challenging.
Thus, RNA-binding domains of CPEBs are highly conserved,
with the potential for overlap in transcript recognition8,9.
However, differential roles of CPEBs in developmental
processes suggest that in mammalian systems, CPEB
substitution/compensation is not a generalized mechanism10–13,
although the specific identity of the targets involved remains
unclear. Moreover, the expression of CPEBs in cancer cells is
highly variable, with pro- and anti-tumorigenic roles reported
depending on the system4. For example, suppressive functions of
CPEB1 in fibroblasts14 or CPEB4 in hepatic cancer cells15
contrast with cooperating effects of these proteins to favour cell
cycle progression in HeLa or 293 cells16,17. The underlying basis
for these seemingly opposing roles are unclear, but may reflect the
fact that CPEBs can modulate both 30-end mRNA adenylation
and deadenylation4.
A disease where the functional impact of the CPEB-mediated
translational programming remains unexplored is malignant
melanoma. Melanomas are a paradigm of aggressive tumours
characterized by the largest mutational rate described to date18,
and the accumulation of massive changes in the transcriptome19.
Still, it is unknown whether these alterations affect or are
modulated by cytoplasmic polyadenylation. Similarly, putative
functions of poly(A) tail length alterations remain unexplored in
the context of lineage-specification. This is relevant as melanoma
is a prototype of disease, where tumour cells rewire intrinsic
developmental traits to favour proliferative and metastatic
capabilities20–22. In this context, the best characterized
melanocytic-specific oncogene is the microphthalmia-associated
transcription factor (MITF)23–25. Intriguingly, MITF can be
subject to highly dynamic regulatory mechanisms that either
activate or inhibit expression and function depending on the
specific stage of tumour progression26–29. Whether MITF mRNA
undergoes cytoplasmic polyadenylation is unknown. This lack
of information also applies to other lineage-specific pathways
driven by vesicular trafficking modulators such as RAB proteins,
recently emerging as key components of gene clusters selec-
tively enriched and required by melanoma cells30–33.
To date, the only information on CPEB proteins in melanoma
is limited to CPEB1 as the target of the tumour suppressor
miR-455-5p (ref. 34). Nevertheless, cellular factors affected by
CPEB1-controlled cytoplasmic polyadenylation have yet to be
defined. Similarly, there are no reports of the CPEB family
members CPEB2, CPEB3 and CPEB4 in melanoma. Nevertheless,
CPEB4 is particularly attractive for its overexpression in gliomas
and pancreatic cancer35. In these tumours, CPEB4 was not strictly
necessary for cell proliferation, but was found to act in a non-cell
autonomous manner remodelling the stroma and favouring
angiogenesis in mouse xenografts35. However, as mentioned
above, these roles of CPEB4 (and the corresponding transcripts
involved) may not be universal, in the light of the downregulation
of this protein in hepatocellular carcinomas15, gastric cancer or
haematological diseases4.
Performing a computational analysis of CPEB proteins across
tumour types, we found a high expression of CPEB4 in melanoma
cells. Histological and functional analyses demonstrated a cell
autonomous and lineage-specific dependency of melanomas on
CPEB4, in a manner not shared by other tumour cell types. These
data identify novel melanoma-associated vulnerabilities in this
otherwise histopathologically complex disease.
Results
CPEB4 is upregulated early during melanoma development.
One of the defining features of melanomas is their inherent
metastatic potential36. Pro-angiogenic roles of CPEB4 identified
in pancreatic adenocarcinomas and other pathologies11,35 were of
interest as possible contributors to the aggressive behaviour of
advanced melanomas. CPEB4 was also attractive as in cancer,
this is the only CPEB for which antibodies have been validated
for genome-wide RNA immunoprecipitation and target
identification35. Publicly accessible transcriptomic profiles were
mined for a global evaluation of CPEB4 mRNA expression in
melanoma and to identify possible differences with other
malignancies. The Cancer Cell Line Encyclopedia (CCLE)
offered an ideal platform for comparative analyses as it covers
over 1,000 cell lines of 37 different cancer types collected and
processed in a uniform manner37. Focusing on solid tumours,
melanoma cells were found among the highest expressors of
CPEB4 (Fig. 1a). Intriguingly, while CPEB4 was not exclusive of
melanoma, pairwise analyses identified statistically significant
differences with 18 tumour types, including glioblastoma and
pancreatic cancer (Fig. 1a), where CPEB4 functions and targets
have been addressed in more detail. High CPEB4 mRNA in
melanoma cells was supported by two independent data sets38,39
corresponding to human clinical biopsies (N¼ 198 and 119
cases, respectively) that span across various cancer types
(see Supplementary Fig. 1a). These results were further
validated by quantitative PCR after reverse transcription (qRT-
PCR) in a panel of cell lines from melanoma and other tumour
types (Supplementary Fig. 1b). Histological analyses were then
performed on tissue microarrays containing representative
examples of 15 tumour types (N¼ 108 specimens; see
Supplementary Information for detail). This analysis confirmed
a high CPEB4 expression in melanoma, although again, not
restricted to this disease (see Supplementary Fig. 1c for
comparative analyses with other malignancies with strong,
medium and low CPEB4 staining).
Next, biopsies from lesions containing non-malignant
melanocytes (nevi) and from melanomas at different stages of
progression (Fig. 1b; N¼ 56), were analysed to define whether
CPEB4 upregulation is an early or late event in this disease. Given
the roles of CPEB4 in the control of pro-metastatic factors such as
tissue plasminogen activator35 and the vascular epithelial growth
factor11, we had anticipated an increased expression of CPEB4
towards advanced melanomas. However, CPEB4 was found
upregulated already at early stages in melanoma development
(Fig. 1c,d). Therefore, we questioned whether this early induction
of CPEB4 reflects in the control of essential genes for cell
proliferation, and to which extent these functions are shared with
other tumour types.
Non-redundant roles of CPEB4 in melanoma cell proliferation.
Next, we took advantage of two previously validated short hairpin
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RNAs (shRNAs)35 to deplete CPEB4 in a panel of melanoma cell
lines that recapitulate frequent characteristic oncogenic mutations
in BRAF, NRAS or p53 of this disease (see depletion efficacies in
Fig. 2a). Control and shRNA-expressing cells were injected
subcutaneously in immunosuppressed mice. Curiously, 90% of
implants of shCPEB4-cells failed to grow (Fig. 2a,b), halting
progression even before sizable lesions could be generated that











































































































































































































































































































































Figure 1 | CPEB4 is induced at early stages of melanoma development. (a) CPEB4 mRNA expression in 27 solid tumours including melanoma
extracted from the CCLE data set (CCLE_Expression_Entrez_2012-10-18.res). mRNA levels are normalized by inter-sample variability across the cell lines
included in the data set (RMA-Log2). The number of cell lines from each cancer type is indicated in parenthesis. Box colours represent the P-values from
pairwise comparisons between melanoma and each tumour type. (b) Representative micrographs of sections from the indicated lesions showing CPEB4
staining in pink. Nuclei are counterstained with hematoxylin. Scale bars, 200mm (upper images); and 50mm (lower images). (c) Quantification of CPEB4
staining intensity in the indicated lesion type scored from 0 (negative) to 3 (highest). The number of lesions per category is indicated in Supplementary
Methods. (d) Percentage of CPEB4-positive cells in melanoma lesions (four independent areas were analysed by stained specimen, using hematoxylin as a
reference to estimate total cell number per section; epidermal and stromal cells were excluded from the analysis). w2-test P values (P) are indicated.
NS, non-significant.
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Figure 2 | Essential cell-autonomous role of CPEB4 in melanoma growth. (a) Representative examples of animals subcutaneously implanted with
SK-Mel-28, SK-Mel-103 or UACC-62 cells expressing control shRNA (shC) or CPEB4 shRNA (sh1). Key melanoma-associated mutations in the indicated
cell lines are listed in parenthesis. Panels on the left correspond to immunoblots for visualization of the efficiency of the CPEB4 shRNA-depleting constructs
in the different cell lines. (b) Differential tumour growth upon subcutaneous implantation of cells in immunosuppressed mice in a. N¼ 5 mice per group.
(c, upper) Depletion of CPEB4 in the indicated cell lines upon lentiviral-driven transduction of two validated shRNA for CPEB4 (sh1 and sh2) shown by
immunoblotting using cells expressing a shRNA control (shC) as a reference. (lower) Melanoma cell proliferation after transduction of control or CPEB4
shRNAs. Graphs depict relative cell numbers at the indicated time points obtained from three independent experiments in triplicate. (d) Representative
images of SA-b-Gal staining (blue) of the indicated melanoma cell lines expressing control or CPEB4 shRNAs. Scale bars, 20mm. (e) Percentage of
SA-b-Gal-positive cells from d. Error bars represent s.e.m. from three independent experiments. Student’s t-test and ANOVA P values are indicated or
represented as ***Po0.001, **Po0.01. ANOVA, analysis of variance.
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considering the reported situation in pancreatic cancer cells,
where CPEB4 depletion delayed, but did not abrogate xenograft
formation35.
The results above suggested that in contrast to the non-cell
autonomous roles of CPEB4 in pancreatic cancer (related to
remodelling of the stroma)35, this protein could exert a more
pressing role in cell proliferation. Therefore, the depletion of
CPEB4 was assessed in melanoma cells cultured as monolayers in
the absence of other cell types (Fig. 2c). In all cases tested the
two CPEB4 shRNAs promoted an acute abrogation of cell
proliferation (Fig. 2c), with characteristic features of premature
senescence, as determined by staining for b-galactosidase activity
at acidic pH (Fig. 2d,e). These effects were in contrast to the
minor impact of CPEB4 downregulation in the pancreatic cancer
RWP1 (Fig. 3a,b). Similarly, melanoma cells were significantly
more dependent on CPEB4 than HeLa, U251 and 639 V
(Fig. 3a,b), selected as examples of cell lines from cervical
carcinoma, glioblastoma and epithelial sites (bladder cancer),
where CPEB4 roles have been best described4,17,35.
We then tested whether the strict dependency of melanomas
on CPEB4 was due to the fact that these cells do not express other
CPEBs that could act in a compensatory manner. Mining solid
tumours in the CCLE (N¼ 853; Supplementary Fig. 2a–c), and
validating mRNA levels experimentally by qRT-PCR (N¼ 20;
Supplementary Fig. 3a–c), we found however CPEB1 and CPEB2
to be well expressed in melanomas, with levels even higher than
for the majority of solid tumours analysed. Levels of CPEB3
were rather similar in all cell lines studied (Supplementary Figs 2c
and 3c; see legends for P values of pairwise comparisons to
melanoma). Next, we interrogated whether the depletion of
CPEB4 in melanoma cells could be counteracted by a
compensatory upregulation of other CPEBs. However, qRT-
PCR analyses failed to identify changes in the basal levels of
CPEBs that would be significantly different upon depletion of
CPEB4 in cell lines from melanoma or other tumour types
(Supplementary Fig. 3d–g). Altogether, these results point out to
distinct roles of CPEB4 in melanoma that (i) cannot be
compensated for by other CPEBs and (ii) reflect intrinsic features
of this disease that extend beyond the basal levels of CPEBs across
tumour types.
Normal melanocytes reveal lineage-dependent roles of CPEB4.
Given the higher sensitivity of melanoma cells to CPEB4 deple-
tion, we decided to address the possibility of lineage-specificity in
the requirement of this protein. To this end, CPEB4 was depleted
in normal melanocytes, the melanoma precursors. Primary mel-
anocytes were then freshly isolated from biopsies of normal skin
and transduced with control and CPEB4 shRNAs. Fibroblasts
were also isolated from the same donors for a comparative
analysis of genetically matched normal cells of an unrelated
lineage. Growth curves were performed with respect to UACC-62
as a prototype of aggressive melanoma cells. Importantly, CPEB4
downregulation (Fig. 3c, upper panels) had rather negligible
effects on fibroblasts whereas it reduced the proliferation of
melanocytes (Fig. 3c). As the case of melanomas, melanocytes
also expressed CPEB1, CPEB2 and CPEB3, but these proteins
appear to be unable to compensate for CPEB4 depletion
(Supplementary Fig. 3h). Still, melanocytes maintained their
characteristic phenotype without exhibiting the cytoplasmic and
nuclear-associated morphological features found in melanoma
cells (Fig. 3d).
Overall, these results suggest that melanoma cells may hijack
roles of CPEB4 in cell proliferation already present in normal
melanocytes. However, melanoma cells appear to acquire
additional dependencies on CPEB4 during tumour progression.
Roles of CPEB4 in melanoma not shared by other cell types.
Main known roles of CPEB4 are related to the control of the
second meiotic division in oocytes40, as well as the exit from
mitosis in HeLa17 and HEK-293 cells16. Therefore, the FUCCI
system41 was exploited for real-time imaging of cell cycle
progression in living melanoma cells expressing or made
deficient for CPEB4. This strategy is based on fluorescence-
dependent visualization of cells in the G1 phase by means of a
RFP-Cdt1 fusion protein (red emission), and cells in S/G2/M by
GFP-Geminin (green emission). Real-time videomicroscopy
revealed aberrant mitosis visualized by chromosome
misalignment in metaphase and aberrant cytokinesis in
telophase, after sustained depletion of CPEB4 in melanoma
cells (see Fig. 4a–c, as well as Supplementary Movies 1 and 2 for
comparative analyses of control- or CPEB4-shRNA cells,
respectively). In vivo, defects in centrosome number, spindle
disorganization, improper alignment of chromosomes and
aberrant segregation were also evident by histological evaluation
of CPEB4-depleted mouse xenografts (see Fig. 4d for examples of
paraffin-embedded lesions stained with a-Tubulin and
phosphorylated histone H3, as readouts for spindle formation
and the detection of proliferative cells). Single-cell quantifications
in cultured cells and subcutaneous melanoma lesions in mice
demonstrated that although consistent, mitotic defects in CPEB4-
downregulated melanoma cells were infrequent, with o10%
increase over basal levels detected in the shControl (shC) cells
(Fig. 4b). These results therefore suggested roles of CPEB4 acting
at an earlier stage (that is, before mitosis) in the cell division cycle.
To evaluate this possibility, cell cycle progression was analysed in
greater detail by flow cytometry in melanoma versus non-
melanoma lines (UACC-62 and HeLa) transduced with control or
CPEB4 shRNAs. As shown in Fig. 4e, BrdU incorporation
revealed a distinct decrease in S-phase population of CPEB4-
depleted melanoma cells (see quantification in Fig. 4f). Analysis
of cell cycle entry after thymidine block confirmed a marked
inability to progress through G1-S in melanoma cells, with
virtually no changes in the cell cycle profile of the HeLa
counterparts (Supplementary Fig. 4). Together, these results
demonstrate a new role of CPEB4 in G1/S transition in melanoma
superseding a secondary function in mitotic control.
RIP-Seq identifies new melanoma-enriched CPEB4 targets.
Next, RNA immunoprecipitation followed by RNA sequencing
(RIP-seq) was performed for an unbiased identification of
CPEB4-bound transcripts that are involved in the modulation of
mitosis and the lineage-specific control of G1/S transition. In this
context, we were interested in genes or pathways that may act
beyond the control of pigmentation (that is, to identify true
novel melanoma-associated traits). The melanoma SK-Mel-103
was selected for an initial screen, as a well-known example of
MITF-negative amelanotic melanoma cells31. RNA collected from
control or shCPEB4-transduced cells (two independent replicates
each) was subjected to crosslinking and immunoprecipitation
followed by elimination of ribosomal RNA (total reads are
summarized in Supplementary Fig. 5a). Reads were aligned to the
human genome (Ref Seq GRCh37/hg19) with TopHat-2.0.4
(ref. 42). For each read, we considered the best hit or allowed 20
multi-hits, obtaining an 80–85% overlap with the two approaches
(Supplementary Fig. 5b). We thus proceeded with the best hit for
subsequent analyses of differential expression. This was
performed using Cufflinks or EdgeR, which rendered similar
results as indicated by the high correlation found by Pearson and
Spearman rank tests (Fig. 5a; see also Supplementary Fig. 5c).
Filtering for significance (adjusted P valueo0.05), this approach
rendered 331 CPEB4-bound transcripts in melanoma cells
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Figure 3 | Increased sensitivity of melanoma cells to CPEB4 depletion. (a) Immunoblots showing CPEB4 levels upon transduction of control or CPEB4
shRNAs in a panel of melanoma (red) and non-melanoma (black) cell lines. (b) Colony formation assays of the indicated tumour cell lines seeded at high or
low density (5 104 or 2–4 103 cells, respectively). Bar graphs correspond to cell number estimated by crystal violet staining and represented with
respect to shC-transfected cells. Data are plotted as means±s.e.m. of three independent experiments in duplicate. (c) Depletion of CPEB4 (by shRNA) in
genetically matched pairs of human skin fibroblasts and melanocytes visualized by immunoblotting (upper) with respect to shC-transduced cells.
The human melanoma cell line UACC-62 is included as a reference. Data are represented as means±s.e.m. of two experiments in triplicate.
(d) Micrographs showing morphological changes driven by shCPEB4 in primary fibroblasts, melanocytes and UACC-62 melanoma cells. Scale bars, 20 mm
(unless otherwise indicated). ***Po0.001, *Po0.05. NS, non-significant.
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(that is, downregulated in the CPEB4 shRNA counterparts; see
additional detail in Supplementary Data 1). Similar analyses were
performed for CPEB4 RIP-Seq in the pancreatic RWP1 cell line
(which had also been performed in duplicates)35. Intriguingly, the
overlap between RIP-Seq data of both systems was strikingly low
(see Fig. 5b for one of the replicates of SK-Mel-103 and of RWP1,
and Supplementary Fig. 5d for the rest of the comparisons). Thus,
while known targets of CPEB4 such as the metallothionein
proteins MT2A and MT1E were found in both cell types, 93% of
the CPEB4-bound transcripts in melanoma (that is, 312/331) had
not been reported in RWP1 (Supplementary Fig. 5e). Indeed,
Gene Set Enrichment Analyses (GSEA) performed in the CCLE,
indicated the CPEB4-bound targets in melanoma showed a
distinct expression in this tumour type (see enrichment scores in
Fig. 5c; the corresponding heatmaps in Fig. 5d; false discovery
rate (FDR)¼ 0.22). Therefore, these results support the
hypothesis that CPEB4 has functions restricted to melanoma
resulting (at least in part) from the regulation of a set of genes
particularly enriched in this tumour type.
Data from RIP-Seq generated in SK-Mel-103 and RWP1 were
further analysed to better identify biological processes that may
ultimately account for the strict requirement of CPEB4 in
melanocytic cells. Using Cytoscape and the ClueGO plug-in for
network visualization, 117 gene ontology (GO) clusters were
identified in SK-Mel-103 (P-values corrected for multiple testing
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Figure 4 | Cell cycle defects in CPEB4-depleted melanoma. (a) Time-lapse analysis of aberrant mitosis in cell line SK-Mel-103 labelled with RFP-Cdt1 and
GFP-Geminin fusion proteins (FUCCI system)41 and transduced with control or CPEB4 shRNAs (see Supplementary Movies 1 and 2 for real time imaging of
this process in shC- and shCPEB4-transduced cells, respectively). (b) Quantification of cells undergoing normal or aberrant mitosis or blocked in G1 from
experiments shown in a. (c) Confocal imaging of mitotic alterations of cultured UACC-62 melanoma cells expressing control or CPEB4 shRNA. DNA and
spindles were visualized by DAPI (blue) and a-Tubulin (green) immunofluorescence, respectively. (d) Aberrant mitosis detected by confocal
immunomicroscopy in xenografts generated with UACC-62 or SK-Mel-103 cells expressing control or CPEB4 shRNAs. Proliferating cells were identified by
phospho-Histone 3 (red immunofluorescence). DAPI (blue) and a-Tubulin (green) were used to label DNA and spindles, respectively. (e) Cell cycle profiles
of UACC-62 and HeLa cells infected with lentiviruses coding for control or CPEB4 shRNA (see depletion in the immunoblots of the upper panels). Shown
are flow cytometry plots of the indicated cells processed to visualize BrdU incorporation. (f) Distribution of the indicated cell populations at the different
phases of the cell cycle. The percentages of cells at the G0/G1, S or G2/M phases were determined by BrdU and PI staining.
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represented GO term was ‘Cell Cycle’, with 44 highly interrelated
GO-associated sub-clusters (see Fig. 6a). Related interconnected
networks were (i) ‘Cell Cycle Checkpoints’, (ii) ‘Chromatin
Organization and DNA Conformation Change’, (iii) ‘DNA
Metabolism’ and (iv) ‘Microtubule Cytoskeleton Organization’,
among others. Intriguingly, these gene clusters showed a
minimum overlap with the GO-enriched terms in pancreatic
cancer cells (Supplementary Fig. 6a). Specifically, CPEB4 was
found to bind transcripts of some mitotic genes (such as BIRC5 or
CENPU) in pancreatic cells, but the majority of the enriched
functions were related to metabolism, ribosome biogenesis,
macromolecule localization and organization, intracellular trans-
port and various catabolic processes (Supplementary Fig. 6b;
Supplementary Data 3), consistent with previous roles of CPEB4
in the secretion of pro-metastatic factors35. Therefore, these results
significantly expand targets and functions of CPEB4. Moreover,
the lack of concordance between melanoma and pancreatic cancer
cells may account for the differential dependency of these cells on
CPEB4 described above (Figs 3 and 4e,f).
PAT-assays validate CPEB4 targets enriched in melanoma cells.
The 331 CPEB4-bound transcripts identified by RIP-seq in
melanoma were subsequently filtered by customized prediction
algorithms for the identification of transcripts with optimally
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Figure 5 | RIP-Seq (RNA immunoprecipitation-sequencing) for the identification of CPEB4 targets in melanoma. (a) Correlated results of Cuffdiff or
EdgeR-based analysis of CPEB4 RIP-seq analyses in SK-Mel-103, using shCPEB4-derivatives as a reference. This comparison was performed in two
independent replicates. Graph depicts differential expression changes (Log2 fold change, Log2FC) obtained with each method for replicate (1). Replicate (2)
is shown in Supplementary Fig. 5c. (b) Differential expression of CPEB4-bound mRNAs in SK-Mel-103 versus the RWP1 pancreatic cancer cell line. RIP-seq
data from RWP1 was obtained from ref. 35 and analysed as for melanoma cells by Cuffdiff. Two replicates were processed for each cell line. Data in this
panel correspond to Replicate (1) of melanoma and pancreatic cancers. Other replicates are depicted in Supplementary Fig. 5d. (c) Relative expression of
CPEB4-bound mRNAs identified by RIP-seq in SK-Mel-103 cells and mined by GSEA across the CCLE data set. Graph represents the enrichment score in
melanoma versus other tumours. Positive correlated genes in melanoma and negatively correlated in other tumours are highlighted in red and blue,
respectively. (d) Heatmap from the GSEA analysis shown in c, represented for each of the indicated tumour cell types. Note the distinct clustering in
melanoma. Pearson coefficient (P), Spearman rank correlation coefficient (r) and FDR values are indicated in the corresponding panels.
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Specifically, these computational methods take into account the
number and localization of CPEs (50-UUUUA1-2U) with respect
to polyadenylation hexanucleotides (HEX), AU-rich elements
(ARE) and binding sites for the Pumilio RNA-binding
protein (PBS), all influencing competency for cytoplasmic
polyadenylation43 (see Supplementary Methods and Fig. 7
below for additional information on the specific sequences
analysed, which include also non canonical variants of CPE and
HEX). This computational analysis resulted in 226 CPEB4-bound
mRNAs with bona fide CPEs (Supplementary Data 4a). These
CPE-containing mRNAs were further analysed using Ingenuity
Pathway Analysis (IPA) (Fig. 6b). This revealed a narrower set of
genes in ‘Cell Cycle’ and ‘Cell Growth and Proliferation’
categories (corrected P value¼ 2.75 10 12 and P¼ 9.75 10 9,
respectively, Fig. 6b; see complete gene lists in Supplementary
Data 4b–d). Interestingly, although the number of genes in these
categories was large (N¼ 106), they were cohesively
interconnected around four nodes, which were found to centre
on BUB1, CDK1, TOP2A or MAD2L1, classical mitosis
checkpoint controllers (Fig. 6c). Linked to these factors were
also multiple key cell cycle regulators (for example, BUB1B),
and oncogenes such as the chromatin remodeler DEK, which
we had previously reported with key roles in the maintenance
of the proliferative capacity of melanoma cells44,45. All
these genes contained multiple CPEs, HEX and PBS in their
30-UTR (Fig. 7), as expected for transcripts regulated by cytosolic
polyadenylation43.
It would be informative, albeit not practicable, to validate each
of the 106 transcripts mentioned above as direct CPEB4 targets.












































































































































































































































Figure 6 | RIP-Seq identifies cell cycle regulators and lineage-specific oncogenes as novel CPEB4 targets. (a) Interaction networks of the GO-terms
(database 02.10.2015) enriched in the CPEB4-bound transcripts identified by RIP-seq in SK-Mel-103. Data were plotted using Cytoscape v3.2.1 and the
ClueGO plug-in v2.1.7 (see GO-terms networks of RWP1 pancreatic cell line in Supplementary Fig. 6a). Numbers correspond to GO-gene sets further
described in Supplementary Data 2. Node sizes represent the statistical significance of the terms (***Po0.0005; **Po0.005; *Po0.05). Supplementary
Data 2 contains detailed information on the CPEB4-bound transcripts and the specific genes in the 117 identified clusters. Supplementary Data 3 lists
GO-enriched categories for CPEB4-bound targets in RWP1 pancreatic cancer cells to demonstrate the minimum overlap with the melanoma SK-Mel-103.
(b) IPA of functional categories enriched in CPE-containing transcripts identified by CPEB4 RIP-Seq in SK-Mel-103. (c) Protein–protein interaction network
of the genes included in the IPA ‘cell cycle’ and ‘cellular growth and proliferation’ clusters of b analysed by STRING and Cytoscape for the visualization of
signalling hubs recognized by CPEB4 in melanoma cells (see Supplementary Fig. 7 for validation of selected CPEB4 direct targets).
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BUB1B, CDK1 and DEK for validation of mitosis CPEB4-related
oncogenic hubs. The requirement of CPEB4 to maintain the
expression of BUB1B, CDK1 and DEK was confirmed by protein
immunoblotting after shRNA depletion in three cell lines from
melanoma (SK-Mel-28, SK-Mel-103 and UACC-62), using other
three non-melanoma lines (RWP1, HeLa and U251) as a
reference (Supplementary Fig. 7a; note the modest or inconsistent
downregulation of the analysed genes by CPEB4 depletion in the
non-melanoma lines with respect to the downregulation in the
melanoma cells). Furthermore, additional RNA-immunoprecipi-
tations demonstrated binding of CPEB4 to the 30-UTR of BUB1B,
CDK1 and DEK mRNAs in melanoma cells (Supplementary
Fig. 7b–d). In addition, poly(A) tail tests (RNA-ligation-coupled
RT-PCR) confirmed the shortening of the poly(A) tail and the
destabilization of these three mRNAs upon CPEB4 depletion in
melanoma, but not in other cell types (Supplementary Fig. 7e).
Together, these results emphasize a distinct impact of CPEB4 in
the regulation of key mitosis-associated oncogenic networks in
melanoma.
CPEB4 controls lineage-specific melanoma drivers. Down-
regulation of BUB1B, CDK1 and DEK provides a mechanistic
explanation for the aberrant spindles and defects in cytokinesis
observed after sustained depletion of CPEB4 in melanoma cells
(Fig. 4a–d). However, these genes cannot account for the acute
and melanoma-enriched G1 arrest after CPEB4 downregulation,
and could not explain why melanomas would be more dependent
on this polyadenylation factor than other tumour types. The
CPEB4 RIP-seq networks mentioned above in SK-Mel-103
(Fig. 6b,c) were then further screened for genes with unique
functions in melanoma. This identified RAB27A (Fig. 6c), a vesicle
trafficking modulator known for its essential roles in melanosome
maturation (a defining trait of this cell lineage)46. Moreover,
RAB27A is upregulated during melanoma progression and it is
required for cell division, although by still incompletely defined
mechanisms22. Although not expressed in SK-Mel-103, we
questioned whether CPEB4 could also control an upstream
modulator of RAB27A, the transcription factor MITF. MITF was
relevant as the prototypical lineage-specific oncogene in
melanocytic tumours47. Interestingly, we found the MITF 30-UTR
to contain the largest amount of CPEs, HEX and PBS of all the
genes analysed, which as the case for RAB27A were predicted by
our computational models to be optimally organized for the control
by cytoplasmic polyadenylation (Fig. 7). Therefore, we set to test
the functional impact of CPEB4 in the levels and polyadenylation
status of both, MITF and RAB72A in additional melanoma cell
lines and in tissue specimens (Figs 8 and 9, respectively).
To demonstrate the impact of cytoplasmic polyadenylation on
MITF, CPEB4 was downregulated in SK-Mel-28 and UACC-62
(two representative pigmented melanoma cell lines) using
validated CPEB4 shRNAs (Fig. 8a). In both cases, the absence
of CPEB4 resulted in a marked inhibition of MITF-M, the most
abundant MITF isoform in melanoma cells48, as shown in Fig. 8a.
HEXNC (AAGAAA, AAUACA, AAUAGA, AAUAUA,
AAUGAA, ACUAAA, AGUAAA, CAUAAA, 
GAUAAA, UAUAAA)
HEX (AAUAAA, AUUAAA)CPE (UUUUAU, UUUUAAU)
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Figure 7 | 30-UTR map of CPEB4 targets. Schematic representation of binding sites for cytoplasmic polyadenylation-associated factors located at the
30-UTR of selected CPEB4 targets identified by RIP-seq in melanoma cells. The content and combination of these binding sites were identified and analysed
by the customized algorithm described in ref. 43 for the prediction of their potential regulation by cytoplasmic polyadenylation. ARE, AU-rich element;
CPE, cytoplasmic polyadenylation element; CPENC, non-consensus CPE; HEX, polyadenylation hexanucleotide; HEXNC, non-consensus hexanucleotide;
PBS, Pumilio-binding site.
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Figure 8 | CPEB4-driven control of the lineage-specific transcription factor MITF. (a) Impact of CPEB4 depletion (by shRNA) on the protein levels of
MITF and the indicated targets shown by immunoblotting in two independent melanoma cell lines. (b) Relative levels of MITF mRNA immunoprecipitated
with antibodies for CPEB4 or rabbit IgG in UACC-62. Cells transduced with shCPEB4 were set as a reference for specificity. mRNA levels were normalized
against expression in the inputs (that is, parental or shCPEB4-expressing cells) and are represented as means±s.e.m. from triplicates. (c) PAT
(polyadenylation length test) of MITF 30-UTR in shC or shCPEB4-transduced melanoma cells. RNase H was used for poly(A) tail removal to define the
specificity of the amplification procedure as previously described35. (d) Paraffin embedded sections of mouse xenografts generated with UACC-62
expressing shC or shCPEB4, and processed for immunohistochemical detection of MITF protein (brown signal). Nuclei were co-stained by hematoxylin.
Scale bars, 50mm. (e) Bar graphs depicting the staining intensity and fraction of MITF-positive cells per section in xenografts generated as in d. Data are
represented as means±s.e.m. from N¼ 5 tumours per group. (f) Relative expression of MITF mRNA in xenografts generated as in d determined by
quantitative qRT-PCR. (g) MITF and CPEB4 mRNA expression in 471 melanoma specimens from the TCGA database. Melanomas are ranked by expression
of CPEB4 (from left to right), which is represented by the black line. Grey lines indicate MITF expression in each sample and the moving average is
represented by the red line. P value of Spearman correlation analyses is indicated. (h) Immunohistochemical detection of CPEB4 (pink) and MITF (brown)
in consecutive sections of a representative metastatic melanoma specimen. Shown are three areas with low (1), intermediate (2) and high (3) CPEB4
staining. Note the parallel expression of both proteins. Stainings were repeated in five independent specimens obtaining similar results. Scale bars, 200mm
(left images); and 50mm (right images). Student’s t-test P values (P) are indicated in the corresponding panels.
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Next, RIP-qPCR and PAT-assays were performed to confirm
direct binding of CPEB4 to the MITF 30-UTR and the subsequent
poly(A) shortening CPEB4 depletion (see Fig. 8b,c). MITF
protein and mRNA were then assessed in mouse xenografts
generated with control or CPEB4-transduced shRNAs. As shown
in Fig. 8d,e, downregulation of CPEB4 resulted in a marked
reduction of MITF protein. Further supporting shortened poly(A)
tail affecting transcript stability (Fig. 8c), MITF mRNA levels
were relatively lower in CPEB4 depleted versus parental mouse
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target of CPEB4, two short guide RNAs were generated for
CRISPR/Cas9-mediated gene depletion. As shown in
Supplementary Fig. 8a,b, CPEB4 sgRNAs promoted a marked
inhibition of MITF in pigmented melanoma cells with the
consequent blockade of cell proliferation.
To further address the physiological impact of these results, the
Cancer Genome Atlas (TCGA) was mined to assess the relative
expression of CPEB4 and MITF in human melanoma specimens
(N¼ 441). As shown in Fig. 8g, a positive correlation was indeed
found in mRNA levels of both genes (P¼ 8.438 10 9).
In parallel, immunohistochemical analyses in representative
examples of human melanoma lesions showed that although
MITF protein expression was highly variable as expected25,49,
it was also positively correlated with CPEB4 levels (see areas with
low, intermediate and high levels of both CPEB4 and MITF in
Fig. 8h). Interestingly, depletion assays demonstrated that the
requirement of CPEB4 to maintain MITF levels was also found to
extend to normal melanocytes, the cells or origin of melanomas
(Supplementary Fig. 8c). Together, these results link for the first
time CPEB4 to the regulation of inherent features of melanocytic
lineage.
RAB27 as a fail-safe control of melanoma cell proliferation. As
mentioned above, RAB27A is a well-known transcriptional target
of MITF. However, additional mechanisms of regulation of
RAB27A may exist as this gene can maintain its expression
despite multiple post-translational events that can dampen MITF
activity26–29. Therefore, since we had identified RAB27A as a
CPEB4-binding transcript (Fig. 6c), we questioned whether
cytoplasmic polyadenylation could sustain the expression of
RAB27A (and thus, its functions in cell proliferation) even in the
absence of MITF. To this end, CPEB4 was downregulated by
lentiviral-driven transfer of shRNA, or by two guide RNAs for
CRISPR/Cas9 gene depletion (Fig. 9a and Supplementary
Fig. 8a,b) in MITF-negative and -positive cell lines (SK-Mel-103
and UACC-62, respectively). In both cases (particularly for
MITF-deficient melanoma cells) RAB27A levels were reduced in
the absence of CPEB4 (Fig. 9a and Supplementary Fig. 8a,b). Of
note, normal melanocytes were also found dependent on CPEB4
to sustain RAB27A expression (see Supplementary Fig. 8c for
inhibitory effects of CPEB4 shRNA on these cells determined by
immunoblotting).
Next, PAT-assays were used to demonstrate that CPEB4
indeed modulated RAB27A mRNA polyadenlyation. As shown in
Fig. 9b, RAB27A poly(A) tail was shortened after CPEB4
depletion, downstream of binding to the 30-UTR of RAB27A,
as supported by amplification of this region upon RNA
immunoprecipitation (Fig. 9c). Functionally, as the case for
CPEB4, the reduction of RAB27A expression (mimicked with a
validated shRNA) also promoted G1 arrest (see flow cytometry
analyses in Fig. 9d,e). Therefore, these results identify poly-
adenylation as a new mechanism of regulation of RAB27A,
distinct from the classical transcriptional control by MITF50, and
the GDP-GTP exchange characteristic of small GTPases51.
A corollary of the data above is that RAB27A and CPEB4
expression should be tightly correlated in vivo. Histopathological
examination of mouse subcutaneous xenografts generated with
control or CPEB4-shRNA transduced melanoma cell lines
showed a marked reduction of RAB27A protein (see Fig. 9f,g,
for matched pairs of CPEB4 positive and negative lesions
generated with two independent cell lines and the corresponding
quantifications). RNA extraction from these CPEB4-deficient
murine lesions confirmed the expected reduction in RAB27A
mRNA (Fig. 9h). These results were further confirmed in human
metastatic melanomas. Immunofluorescence imaging by confocal
microscopy of human melanomas (Fig. 9i), followed by single-cell
quantification analyses in whole-tissue sections (Fig. 9j) revealed
that over 90% of cells co-express both proteins (Pearson
correlation P¼ 0.69). Therefore, the histological and functional
results of this study bring physiological relevance to our initial
computational data which had revealed a particular enrichment
















Figure 10 | Proposed mode of action of CPEB4 in melanoma. Summary of
newly identified roles of CPEB4 on lineage-specific melanoma drivers
(MITF and RAB27), superseding a cohesive network of G2/M cell cycle
modulators, both distinct from targets described in pancreatic cancer
(the only other tumour type where CPEB4 function has been analysed as
here, in a genome-wide manner).
Figure 9 | RAB27A as a novel CPEB4-controlled melanoma driver. (a) Immunoblots showing the downregulation of RAB27A protein expression in
MITF-negative (SK-Mel-103) and MITF-positive (UACC-62) cell lines at the indicated times upon lentiviral-driven expression of control or CPEB4 shRNA.
(b) RAB27A mRNA Poly(A) tail shortening visualized by PAT assays in CPEB4-depleted melanoma cells. RNase H was used as a reference control for
poly(A) removal. nt, nucleotides. (c) RAB27A mRNA levels from RIP experiments performed with CPEB4 antibody or IgG control antibody in the indicated
melanoma cells. Inputs were used to normalize mRNA expression in the immunoprecipitated fraction and data are presented as means±s.e.m. from
triplicates. (d) BrdU incorporation in the indicated melanoma cell lines visualized by flow cytometry 4 days after lentiviral-driven expression of control or
RAB27A shRNA. The corresponding cell cycle distribution is shown in e. (f) Micrographs of paraffin-embedded sections of xenografts generated with the
indicated cell lines expressing shC or shRNA against CPEB4, and processed for the visualization of RAB27A (pink staining). Nuclei are counterstained with
hematoxylin. Scale bars, 50mm. (g) Quantification of RAB27A expression represented as a function of positive cells. (h) RAB27A mRNA downregulation
determined by quantitative qRT-PCR in xenografts generated as in f. (i) Mosaic image corresponding to dual immunohistochemistry performed on human
melanoma tumours (whole-lesion analysis) and visualized by confocal microscopy for single-cell quantification of CPEB4 (red) and RAB27A (green). Scale
bars, 1,000mm. Images in the right correspond to higher magnification of three selected areas of the lesion (labelled as 1, 2 and 3; scale bars, 100mm)
demonstrating the correlation between these two proteins. (j) Relative expression of CPEB4 and RAB27A quantified at a single-cell level by an intelligent
matrix screening remote control tool (iMSRC) from images processed by the Definiens XD software. Data points were pseudo-coloured to separate cells
with dual expression of CPEB4 and RAB27A (yellow) from those with dominance of one of the two proteins (green for RAB27A and red for CPEB4).
Student’s t-test P values (P) are indicated in the corresponding panels. iMSRC, intelligent matrix screening remote control.
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(Supplementary Fig. 8d). Specifically, here we show that by
overexpressing CPEB4, melanoma cells can ensure an efficient
progression through the cell cycle (through newly identified gene
networks that act at G1/S and G2/M checkpoints), while
maintaining lineage-specific identity via an independent control
of MITF and RAB27A.
Discussion
Lineage-specificity in cancer can be achieved by genes that are
either uniquely expressed in precursor cells (usually as part of
signalling cascades that define cell identity), or by factors that
being ‘common’ to other malignancies, are distinctively regulated
and required for a selected tumour type52,53. Here we
demonstrate that in melanoma cells, these two mechanisms can
be coordinately controlled by CPEB4: (i) by modulating the
expression of MITF and RAB27A, essential drivers of intrinsic
melanocytic-associated functions; and (ii) by enriching the
expression of key oncogenic signalling hubs (see model in
Fig. 10). These data therefore provide new insight on mechanisms
underlying melanoma progression and uncover unexpected
tumour-specific actions of cytoplasmic polyadenylation in this
disease.
Melanomas deregulate a broad spectrum of (epi)genetic
alterations which ultimately impinge at multiple levels on cell
cycle checkpoint controls36,54–57. Consequently, it could perhaps
have been anticipated that melanomas behaved in a similar
manner as aggressive pancreatic cancers, namely, being able to
sustain CPEB4 depletion without affecting cell cycle
progression35. Indeed, our data revealed that melanomas -as
other tumour types- express other CPEB family members
(particularly CPEB1 and CPEB2), which could have acted in a
compensatory manner in the absence of CPEB4. Yet, one of the
most unexpected findings of this work was the acute abrogation
of cell proliferation in CPEB4-downregulated melanoma cells
(a feature we could trace back to normal melanocytes). The
minimal overlap in the CPEB4-bound transcripts in melanoma
and pancreatic cancers is striking, considering that up to 20% of
the transcriptome has been proposed to be controlled by
cytoplasmic polyadenylation17. Therefore, the extent to which
CPEBs may substitute for or cooperate with CPEB4 in other
tumour types deserves further attention. Furthermore, it should
be taken into consideration that CPEBs may act as activators or
repressors of translation depending on their binding partners and
cellular context9. For example, an attractive possibility is that the
RNA maps controlled by CPEB4 are wired in a differential
manner depending on whether this protein is overexpressed or
downregulated. These studies may be further complemented with
the analysis of 30-UTRs with non-canonical CPE sites, which may
also be regulated by CPEB4 as suggested by our RIP-Seq data.
The G2/M transition modulators identified as CPEB4 targets in
melanoma provide a mechanistic explanation for the aberrant
mitosis observed in vitro and in vivo upon depletion of this
protein. In this context, transcripts associated with spindle
assembly and chromosome segregation found here for CPEB4
in melanoma reflect mitotic roles of CPEB1 first described in
Xenopus oocytes58. These results therefore support an attractive
scenario whereby CPEB4 may have acquired pro-mitotic
functions of CPEB1. However, our data suggest that in
melanoma, this function is superseded by factors that act earlier
in the cell cycle (that is, G1/S transition), and have essential roles
in this tumour type (see model in Fig. 10). Here we showed that
this dependency relies in a cluster of genes selectively enriched in
melanoma, a feature we functionally demonstrated for MITF
and RAB27A. CPEB4 may therefore endow these melanoma-
associated factors for fast tuning, polyadenylating their mRNA in
the cytosol and favouring translation without the time and energy
needed for new transcription, splicing and exit from the nucleus.
This scenario may reflect actions of CPEBs on other cell cycle
regulators such as Cyclin B, Cyclin E1 or E2 in oocytes40. It would
be interesting to determine whether transcriptional roles of MITF
could in turn contribute to the upregulation of CPEB4 at early
stages of melanoma progression, particularly in the context of
classical oncogenic alterations in this disease (for example,
BRAF4MEK or NRAS4PI3K-dependent pathways).
The finding that CPEB4 can control RAB27A independently of
MITF has further translational implications. RAB27A was
initially identified for its role in melanosome biogenesis and
transport50. However, this protein, as other vesicular trafficking
modulators, is raising attention as part of an oncogenic signature
we and others have found to be particularly hyperactivated in
melanoma22,31–33. The presence of CPE sites in the RAB27A
30UTR therefore allows the regulation by polyadenylation to
secure a ‘melanocytic memory’ even in the absence of MITF.
Consequently, CPEB4-controlled pathways could represent
cell type-selective vulnerabilities that could be exploited
therapeutically. Of note, while this study has focused on
melanocytic cells, CPEB4 is expressed (albeit to variable levels)
in other cell types. Therefore, it is tempting to speculate that
CPEB4 may polyadenylate other RAB family members that
modulate protein sorting or secretion for example to modulate
neuronal synaptic plasticity or cell polarity, processes reported to
be controlled by polyadenylation4. Therefore, the RNA
immunoprecipitation analyses performed here provide a rich
resource on CPEB4 controlled signalling cascades that could be
explored as a platform for future comparative analyses across
tumour types and cellular lineages.
Methods
Cells. The human melanoma cell lines SK-Mel-5, SK-Mel-19, SK-Mel-28,
SK-Mel-29, SK-Mel-103, SK-Mel-147, SK-Mel-173, G-361, UACC-62 were
obtained from the Memorial Sloan Kettering Cancer Center, NY, USA and
WM-164 from Dr Herlyn’s laboratory at Wistar Intitute, PE, USA. The
non-melanoma human cell lines 639 V (bladder cancer), HeLa (cervical cancer),
HCT116 (colorectal cancer), T98G (glioblastoma), U251 (glioma), A549
(non-small cell lung cancer), PC3 (prostate cancer) and 293FT (transformed
human embryonic kidney cells) were obtained from ATCC. MiaPaca-2 and RWP1
(pancreatic cancer), as well as HT29 (colorectal cancer) were a gift from Dr F Real’s
laboratory at CNIO. All these tumour cell lines were cultured in DMEM
(Invitrogen) supplemented with 10% fetal bovine serum (Hyclone). Primary
human melanocytes and fibroblasts were isolated as described before59 from
neonatal foreskins. Melanocytes were cultured in Medium 254 supplemented with
1% melanocyte growth factors (HMGS, Cascade Biologics) and 0.2 mM CaCl2;
fibroblasts were cultured in DMEM containing 10% fetal bovine serum. All
primary and tumour cell lines were mycoplasma free as tested by nucleic acid
hybridization-based assays.
Protein immunoblotting. Cells were harvested and total cell lysates were obtained
using RIPA buffer supplemented with protease (Roche Diagnostics) and
phosphatase inhibitors (Santa Cruz). Protein immunoblots were performed
according to standard procedures using Immobilon-P membranes (Millipore).
Primary antibodies used were: CPEB4 (ab830009, Abcam; dilution 1:1,000), DEK
(610948, BD Transduction Laboratories; dilution 1:1,000), BUB1B (612503, BD
Transduction Laboratories; dilution 1:500), CDK1 (sc-54, Santa Cruz Biotechnol-
ogy; dilution 1:500), RAB27A (HPA001333, Sigma; dilution 1:1,000), MITF (Ab-1,
Clone C5, Thermo Scientific; dilution 1:500), TRP2 (sc-54, Santa Cruz Bio-
technology; dilution 1:1,000) and a-Tubulin (clone DM1A, Sigma; dilution
1:10,000). HRP-conjugated secondary antibodies (dilution 1:5,000) were either
anti-mouse (GE Healthcare), anti-rabbit (GE Healthcare) or anti-goat (Jackson
Immunoresearch). When indicated, ImageJ software was used to quantify protein
levels. a-Tubulin was used as loading control. Uncropped scans of the most
important blots are provided in the Supplementary Information (Supplementary
Figs 9–11).
Gene silencing by lentiviral transduction of shRNAs. Stable depletion of CPEB4
was achieved by lentivirus-driven gene silencing using two previously reported
shRNAs35 purchased from Sigma: CPEB4 sh1: 50-GCTGTTGGAAAGACTTGA
TAA-30 and CPEB4 sh2: 50-GCGTTATGTGTTGAACAGTAT-30 . Non-Target
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms13418
14 NATURE COMMUNICATIONS | 7:13418 | DOI: 10.1038/ncomms13418 | www.nature.com/naturecommunications
shRNA: 50-CAACAAGATGAAGAGCACCAA-30 was used as control. Viruses
were produced in 293FT cells and infections were performed as previously
described60. Downregulation efficacy was determined after puromycin selection
(1mg/ml) by protein immunoblotting or RT-qPCR.
Growth curves and colony formation assays. For growth curves, 1 103 tumour
or 5 103 primary cells were plated in 96-well optical bottom plates at day 6 after
lentiviral transduction. At the indicated time intervals, cells were fixed with 4%
paraformaldehyde (Electron Microcopy Sciences) and stained with DAPI
(Invitrogen). For each time point, total cell number was quantified in triplicates by
automated high-throughput confocal detection of DAPI-stained nuclei using the
OPERA HCS platform and the Acapella Analysis Software (Perkin Elmer). Colony
formation assays were performed on six-well plates, each well seeded with 5 104
cells for high density assays or 2–4 103 cells for low density assays onto six-well
plates. Cells were allowed to grow for 7–14 days and the colonies were then stained
with 0.4 g l 1 crystal violet (Sigma). Crystal violet intensity was quantified using
ImageJ software. Unless otherwise indicated, all proliferation and colony formation
assays performed with lentiviral transduced cells were plated at day 6 post trans-
duction. The number of biological and technical replicates for each experiment is
indicated in the figure legends.
Cell cycle progression analyses. For BrdU pulse, exponentially growing
UACC-62 and HeLa cells transduced with control- or CPEB4- shRNAs were
incubated with 10mM BrdU (Sigma) for one hour, essentially as described
elsewere61. S phase (BrdU positive) cells were stained with FITC-conjugated
anti-BrdU antibody (BD Pharmigen) and DNA was counterstained with
50mg ml 1 propidium iodide (PI) (Sigma). For cell synchronization at the G1/S
phase, UACC-62 and HeLa cells were treated with 2.5 mM thymidine (Sigma) for
19 h, starting one day after transduction with control or CPEB4 shRNAs. Cells were
then fixed at 0, 4, 8 and 24 h after release of the thymidine block and DNA
counterstained with 50mg ml 1 PI (Sigma). Data were acquired using a FACS
Calibur flow cytometer (Becton Dickinson). Cell aggregates were excluded using
pulse processing and a minimum of 20,000 single events were measured. Data was
analysed using FlowJo 9.6.4 software (Treestar).
Fluorescence-based cell imaging. Bright-field images of primary fibroblasts,
melanocytes and UACC-62 melanoma cells were acquired 6 days after infection
with lentiviruses coding for control or CPEB4-shRNA, using a Nikon ECLIPSE TiE
fluorescence microscope (Izasa). For visualization of mitotic cells in vitro, control
and shCPEB4-expresing UACC-62 cells were fixed with 4% paraformaldehyde and
stained with a-Tubulin (dilution 1:500) and DAPI, for subsequent imaging with a
20x HCX PL APO 0.7 N.A. oil-immersion objective using a TCS-SP5 (AOBS-UV)
confocal microscope (Leica Microsystems). For time-lapse videomicroscopy of cell
cycle progression, SK-Mel-103 melanoma cells were transduced with RFP-Cdt1
and GFP-Geminin fusion proteins (FUCCI system) as previously reported41.
Control or CPEB4 shRNA infected cells were plated at day 10 post-transduction in
eight-well glass bottom plates, and both fluorescence and bright-field images were
captured every 10 min during 20 h using 20x UPlan Sapo 0.75 N.A. dry objective on
a Delta Vision RT microscope (Applied Precision) coupled to a CO2 and
temperature-controlled incubation chamber. See additional detail on the imaging
systems used in the Supplementary Methods.
Histological analyses. Tissue sections were deparaffinized, incubated overnight
with primary antibodies at 4 C in a humidified chamber and then rinsed and
incubated with fluorescent secondary antibodies for 1 h at room temperature. For
immunohistochemical visualization and quantification of CPEB4 and RAB27A
expression, primary antibodies used were CPEB4 mouse monoclonal clone
ERE93C (dilution 1:50) and RAB27A rabbit antibody HPA001333 (Sigma;
dilution 1:50). Secondary antibodies were anti-mouse Alexa Fluor 555 and anti-
rabbit Alexa Fluor 488 (Life Technologies; dilution 1:400) and DNA was coun-
terstained with DAPI. Negative controls were obtained by omitting the primary
antibody. Image mosaics were acquired at 20HCX PL APO 0.7 N.A. dry
objective using a TCS-SP5 (AOBS-UV) confocal microscope and were processed
with the ‘intelligent matrix screening remote control’ tool essentially as previously
described31. Images were subsequently analysed with Definiens XD software to
determine CPEB4 and RAB27A cytoplasmic intensities per cell. Signal intensities
were quantified in maximum range of RGB colour scale (0–255). Data points were
pseudo-coloured based on red/green signal intensity ratio (red, ratio42; green,
ratioo0.5; yellow, ratio 0.5–2). Signals below 10% of maximum pixel intensity
(25/255) were considered as background and not considered for ratio calculations.
See Supplementary Methods for additional detail on antibodies and quantification
procedures.
RNA immunoprecipitation (RIP). For RNA immunoprecipitation, SK-Mel-103
cells were either left non-infected or were transduced with lentiviruses coding for
CPEB4 shRNA. 6 days after infection cells were fixed at 80% confluence in 1%
formaldehyde for 10 min at room temperature (RT) and were lysed in RIPA buffer
containing protease and RNase inhibitors (Applied Biosystems) essentially as
described before62. Lysates were sonicated in a Bioruptor Standard (Diagenode) for
10 min at low intensity and then precleared. Samples were immunoprecipitated
using anti-CPEB4 antibody (ab830009, abcam) or rabbit IgG (Sigma) coupled to
Dynabeads Protein A (Invitrogen) for 3 h at 4 C. RNA elution was performed by
two consecutive incubations at 55 C for 30 min and at 65 C for 45 min in RIPA
buffer containing 50mg proteinase K (Roche Applied Science), 1% SDS, 200 mM
NaCl and 10 mM EDTA. Supernatants were digested with DNase I for 10 min at
RT and RNA was extracted with TRI Reagent (Sigma) following manufacturer’s
protocol. For RNA sequencing, samples were processed by the CNIO Genomics
Unit as described in the following section. For CPEB4 target validation, three
additional independent RIP experiments were performed in SK-Mel-103 and
UACC-62 cells, non-infected or transduced with CPEB4 shRNA. All
immunoprecipitated RNA and 1 mg of RNA extracted from inputs were
retrotranscribed using SuperScript III Reverse Transcriptase (Invitrogen) and
subjected to quantitative-PCR. Primers for quantitative RT-PCR validation of
candidate genes are described in the Supplementary Materials. Fold enrichment of
target mRNAs in the immunoprecipitated fraction was calculated after
normalization with the gene expression from the inputs.
RNA sequencing and bioinformatic analyses. After RNA immunoprecipitation
RNA integrity was evaluated by Agilent 2100 bioanalyzer using RNA 6000 Pico
kit following manufacturer’s recommendations. Twenty nanograms of RNA
per sample were processed with Ribo-Zero Gold Kit (Epicentre, Cat. No.
RZHM11106/RZG1224) for ribosomal RNAs removal. cDNA libraries were
generated and sequenced on Illumina Genome Analyzer II with SBS TruSeq v5
reagents following manufacturer’s protocols.
Fastq files63 with 40-nt single-end sequenced reads obtained from two
independent RIP-seq experiments were quality-checked with FastQC (Andrews,
http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) and aligned to the
RefSeq human genome annotation data set GRCh37/hg19 (UCSC) with
TopHat-2.0.4 (ref. 42) (using Bowtie 0.12.7 (ref. 64)) and processed with Samtools
0.1.16 (ref. 65), allowing two mismatches. For each read, the alignment with the
best score was considered. An additional alignment was performed allowing 20
multihits for each read (TopHat default value). Assembly of transcripts, estimation
of their abundances and differential expression were calculated with Cufflinks 1.3.0
(ref. 42). EdgeR software66 was used for an alternative analysis of the differential
expression of the transcripts. The transcripts with FPKM expression values lower
than 0.05 in both conditions were excluded of the analysis. Differences were
considered significant when FDR-adjusted P values were lower than 0.05.
Noncoding RNAs were excluded for the final selection of candidates.
The CPEB4-bound transcripts overlapping in RIP-seq replicates were then
mined by GSEA across CCLE data sets, which encompasses 61 cell lines from
melanoma, 44 from pancreatic cancer, and over 900 examples of 37 tumour types.
Genes were ranked based on t statistic value. After Kolmogorov–Smirnoff testing,
those gene sets showing FDR o0.25, a well-established cutoff for the identification
of biologically relevant gene sets67, were considered enriched between classes under
comparison.
CPEB4 targets identified by RIP-Seq in SK-Mel-103 melanoma (this study) and
RWP-1 pancreatic cell lines35 were analysed for significantly enriched (Pr0.05)
GO biological processes (database 02.10.2015) by using Cytoscape68 v3.2.1 and the
ClueGO plug-in69 v2.1.7. For SK-Mel-103 panel, sizes of the nodes reversely
represent the statistical significance of the terms (P-values were subjected to
Bonferroni step down correction for multiple testing). For RWP1 pancreatic cells
enriched GO terms were combined into hubs (Supplementary Fig. 6a; represented
as circles, whose diameter is proportional to the number of gene clusters per hub).
Pearson and Spearman correlation tests were performed to define the correlation in
RIP-seq targets identified in melanoma and pancreatic cancer cells (P and r
coefficient values 40.5 were considered significant).
CPEB4-bound transcripts in melanoma cells were further analysed to predict
their regulation by cytoplasmic polyadenylation. A previously validated prediction
algorithm43 was used to define the translational behaviour of the mRNAs. Briefly,
this algorithm screens 30-UTR regions for the presence of cytoplasmic
polyadenylation-associated factors binding sites such as the cytoplasmic
polyadenylation element (CPE), the polyadenylation hexanucleotide (HEX),
AU-rich elements (ARE) and the Pumilio binding site (PBS). The specific elements
and sequences considered are depicted in Fig. 7. In a second round, the software
analyzes the distribution and combination of the elements to identify ‘activation’
and ‘repression’ motifs in candidate 30-UTRs. mRNAs predicted to be regulated by
cytoplasmic polyadenylation in melanoma were further analysed using IPA tool
(http://www.ingenuity.com/products) and GSEA.
Polyadenylation assays. RNA ligation-coupled RT-PCR was performed as
described70 with some modifications. 4 mg of total RNA extracted from
SK-Mel-103, UACC-62 or RWP1 cells transduced with control or CPEB4 shRNAs
were ligated to 0.4 mg SP2 anchor primer (P-50-GGTCACCTCTGATCT
GGAAGCGAC-30-NH2) using T4 RNA ligase (New England Biolabs). This was
followed by retrotranscription with ProtoScript II reverse transcriptase
(New England Biolabs) using 0.4 mg of ASP2T reverse-anchor primer
(GTCGCTTCCAGATCAGAGGTGACCTTTTT), according to manufacturerś
protocol. cDNA samples were then digested with 2 mg RNase A (Qiagen) and
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amplified by PCR using Platinum Taq polymerase (Invitrogen), ASP2T reverse-
anchor primer and a specific forward primer for each mRNA analysed, following
manufacturer’s instructions. PCR products were resolved in 2% agarose gels for
visualization. Poly(A) tail digestion by RNase H (New England Biolabs) before
RNA ligation in the same initial RNA samples were used as control of the PCR
reaction specificity. The primers used for polyadenylation assays are shown in
Supplementary Methods.
Animal experiments. Mouse xenograft models were generated by subcutaneous
implantation of SK-Mel-28 (2.5 106), SK-Mel-103 (1.0 106) or UACC-62
(5 106) in 8 week-old athymic nude (Crl:NU(NCr)-Foxn1nu) female mice
(Charles Rivers). To this end, cells were harvested at day 7 after transduction with
control or CPEB4 shRNAs, resuspended in 0.1 ml PBS (SK-Mel-103 cells) or
matrigel (BD Bioscience) at 1:3 ratio in PBS (SK-Mel-28 and UACC-62 cells) and
injected in the back of the animals (N¼ 5 per group). Tumour growth was mea-
sured blinded to the experimental conditions at the indicated time intervals.
Tumour volume was estimated using a caliper and calculated as V¼ axb2 0.52,
where ‘a’ stand for the bigger and ‘b’ for the smaller diameter of the tumour. When
control tumours exceeded 1 cm3 size mice were sacrificed and xenografts were
surgically excised and processed for histopathology. All experiments with mice met
the Animal Welfare guidelines and were performed in accordance with protocols
approved by the Ethics Committee of the Instituto de Salud Carlos III.
Statistical analyses. Multi-tumour CPEB4 mRNA expression box plot was
extracted by the CCLE database (http://www.broadinstitute.org/ccle/home)37 using
cBioPortal. Additional cross-tumour profiles in tumour specimens and the
corresponding enrichments in melanoma were extracted from Oncomine from the
data sets indicated in corresponding figure legends. Differential CPEB4 expression
among benign and malignant human melanocytic lesions was evaluated by w2-test.
Cell proliferation and tumour growth curves were analysed by two-way analysis of
variance (mixed model) considering matching among the measures at different
time points. In all the cases Po0.05 was considered significant. When indicated,
P values were represented as follows: ‘***’ for Po0.001, ‘**’ for Po0.01, ‘*’ for
Po0.05 and ‘NS’ for not significant. CPEB4 protein expression was compared
between melanoma and non-melanoma tumour cell lines using two-tailed unpaired
Student’s t-test. RAB27A and MITF differential expression found in murine-
xenografted tumours were analysed by two-tailed unpaired Student’s ’t-test. CPEB4
and RAB27A coexpression in human melanoma specimens was evaluated by
Pearson test (with P40.5 was considered significant). For GSEA, gene sets showing
FDRo0.25 after Kolmogorov-Smirnoff testing were considered enriched between
classes under comparison.
Data availability. RIP-seq data has been deposited in NCBI’s Gene Expression
Omnibus (GEO Series accession number GSE75773). All additional relevant data
and experimental detail, including the bioinformatic tools for CPE identification
are available from the authors upon request.
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